Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chris Pepper

Showing results (41-50 of 114) with videos related to

Pageof 12
Sort By:
Oncotarget|January 26, 2019
PARP inhibition prevents escape from a telomere-driven crisis and inhibits cell immortalisationGreg Ngo, Sam Hyatt, Julia Grimstead, et al.
Cell Cycle (Georgetown, Tex.)|April 16, 2003
Leukemic and non-leukemic lymphocytes from patients with Li Fraumeni syndrome demonstrate loss of p53 function, Bcl-2 family dysregulation and intrinsic resistance to conventional chemotherapeutic drugs but not flavopiridolChris Pepper, Alun Thomas, Terry Hoy, et al.
Immunology|October 7, 2014
CD8<sup>+</sup> T-cell recognition of a synthetic epitope formed by t-butyl modificationReiss A Reid, James E Redman, Pierre Rizkallah, et al.
Leukemia & Lymphoma|December 3, 2005
The P2X7 receptor gene polymorphism 1513 A-->C has no effect on clinical prognostic markers and survival in multiple myelomaShankaranarayana Paneesha, Jane Starczynski, Chris Pepper, et al.
Leukemia|February 24, 2019
Telomere fusions associate with coding sequence and copy number alterations in CLLLaura Escudero, Kez Cleal, Kevin Ashelford, et al.
Pharmacoeconomics|December 6, 2011
Dronedarone for the treatment of atrial fibrillation: a NICE single technology appraisalClaire McKenna, Emma Maund, Muhammad Sarowar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2005
Common polymorphism G(-248)A in the promoter region of the bax gene results in significantly shorter survival in patients with chronic lymphocytic Leukemia once treatment is initiatedJane Starczynski, Chris Pepper, Guy Pratt, et al.
Pharmacoeconomics|April 27, 2013
Dabigatran for the prevention of stroke and systemic embolism in atrial fibrillation: A NICE single technology appraisalRita Faria, Eldon Spackman, Jane Burch, et al.
Blood|March 19, 2014
Development and characterization of a physiologically relevant model of lymphocyte migration in chronic lymphocytic leukemiaElisabeth Walsby, Andrea Buggins, Stephen Devereux, et al.
Leukemia Research|February 7, 2006
Two germ line polymorphisms of the tumour suppressor gene p53 may influence the biology of chronic lymphocytic leukaemiaGeothy Kochethu, Julio Delgado, Chris Pepper, et al.
Pageof 12

Showing results (41-50 of 114) with videos related to

Sort By:
Pageof 12
Oncotarget|January 26, 2019
PARP inhibition prevents escape from a telomere-driven crisis and inhibits cell immortalisationGreg Ngo, Sam Hyatt, Julia Grimstead, et al.
Cell Cycle (Georgetown, Tex.)|April 16, 2003
Leukemic and non-leukemic lymphocytes from patients with Li Fraumeni syndrome demonstrate loss of p53 function, Bcl-2 family dysregulation and intrinsic resistance to conventional chemotherapeutic drugs but not flavopiridolChris Pepper, Alun Thomas, Terry Hoy, et al.
Immunology|October 7, 2014
CD8<sup>+</sup> T-cell recognition of a synthetic epitope formed by t-butyl modificationReiss A Reid, James E Redman, Pierre Rizkallah, et al.
Leukemia & Lymphoma|December 3, 2005
The P2X7 receptor gene polymorphism 1513 A-->C has no effect on clinical prognostic markers and survival in multiple myelomaShankaranarayana Paneesha, Jane Starczynski, Chris Pepper, et al.
Leukemia|February 24, 2019
Telomere fusions associate with coding sequence and copy number alterations in CLLLaura Escudero, Kez Cleal, Kevin Ashelford, et al.
Pharmacoeconomics|December 6, 2011
Dronedarone for the treatment of atrial fibrillation: a NICE single technology appraisalClaire McKenna, Emma Maund, Muhammad Sarowar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2005
Common polymorphism G(-248)A in the promoter region of the bax gene results in significantly shorter survival in patients with chronic lymphocytic Leukemia once treatment is initiatedJane Starczynski, Chris Pepper, Guy Pratt, et al.
Pharmacoeconomics|April 27, 2013
Dabigatran for the prevention of stroke and systemic embolism in atrial fibrillation: A NICE single technology appraisalRita Faria, Eldon Spackman, Jane Burch, et al.
Blood|March 19, 2014
Development and characterization of a physiologically relevant model of lymphocyte migration in chronic lymphocytic leukemiaElisabeth Walsby, Andrea Buggins, Stephen Devereux, et al.
Leukemia Research|February 7, 2006
Two germ line polymorphisms of the tumour suppressor gene p53 may influence the biology of chronic lymphocytic leukaemiaGeothy Kochethu, Julio Delgado, Chris Pepper, et al.
Pageof 12